Filing Flows

Filing Flows › Companies › Crinetics Pharmaceuticals › Cash flow

Crinetics Pharmaceuticals cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$94.7M in Q2 2026 · −$425M over twelve months

Operating cash flow−$94.2M
Capital spending−$521K
Free cash flow−$94.7M
Cash conversion cycle-5752 days

Analysis

In Q2 2026, Crinetics Pharmaceuticals generated −$94.2M of operating cash flow and spent $521K on capital projects, leaving free cash flow of −$94.7M. That is $5.7M less than in Q2 2025 (−$89.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$423M; the largest uses were operating cash flow ($423M), capital spending ($2.7M), other investing ($1.5M); besides operations, cash came from shares issued ($381M), other financing ($47.4M); the cash balance rose by $1.3M.

Operating cash flow was −$94.2M against net income of −$121M. The largest differences: stock-based pay +$24.9M, payables +$9.3M, receivables −$6.3M.

Its cash conversion cycle was -5752 days (receivables 32 + inventory 1936 − payables 7719): suppliers fund its working capital.

Free cash flow

Crinetics Pharmaceuticals: free cash flow by quarterCrinetics Pharmaceuticals: free cash flow by quarter−$63.4MQ3 2024−$67.9MQ4 2024−$89.7MQ1 2025−$89.1MQ2 2025−$112MQ3 2025−$93.4MQ4 2025−$126MQ1 2026−$94.7MQ2 2026
Operating cash flow less capital spending.
Crinetics Pharmaceuticals: operating cash flow against capital spendingCrinetics Pharmaceuticals: operating cash flow against capital spendingOperating cash flowCapital spending−$62.8M$528KQ3 2024−$66.9M$1.0MQ4 2024−$88.5M$1.2MQ1 2025−$85.9M$3.2MQ2 2025−$111M$863KQ3 2025−$92.9M$458KQ4 2025−$125M$820KQ1 2026−$94.2M$521KQ2 2026
Latest (Q2 2026): Operating cash flow −$94.2M, Capital spending $521K.

Capital allocation, year by year

Crinetics Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearCrinetics Pharmaceuticals: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$88.6MFY2021: Shares issued $253MFY2021: Capital spending −$436K$253MFY2021FY2022: Operating cash flow −$115MFY2022: Shares issued $122MFY2022: Capital spending −$1.7M$122MFY2022FY2023: Operating cash flow −$169MFY2023: Shares issued $389MFY2023: Capital spending −$4.7M$389MFY2023FY2024: Operating cash flow −$230MFY2024: Shares issued $1.0BFY2024: Capital spending −$3.8M$1.0BFY2024FY2025: Operating cash flow −$378MFY2025: Capital spending −$5.8MFY2025
Over these 5 years operating cash flow totalled −$981M; the largest uses were operating cash flow ($981M) and capital spending ($16.4M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$1.2B
Debtnone
Net cash$1.2B
Cash runway2.8 years

Crinetics Pharmaceuticals is burning cash: its operations consume cash, a free cash flow of −$425M a year at the current rate against $1.2B of cash and investments: a runway of about 2.8 years before any new financing.

Where the cash came from and went

Crinetics Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Crinetics Pharmaceuticals: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$94.2MCash drawn (+) / kept (−)$58.8MOther investing$26.8MShares issued$8.9MCapital spending−$521KExchange rates$132K
Crinetics Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Crinetics Pharmaceuticals: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$423MShares issued$381MOther financing$47.4MCapital spending−$2.7MOther investing−$1.5MCash drawn (+) / kept (−)−$1.3MExchange rates$18K

From profit to cash

Crinetics Pharmaceuticals: net income to operating cash flow, Q2 2026Crinetics Pharmaceuticals: net income to operating cash flow, Q2 2026Net income−$121MDepreciation & amortization$1.1MStock-based pay$24.9MReceivables−$6.3MInventory−$358KPayables$9.3MDeferred revenue$516KPrepaid and other assets−$463KOperating cash flow−$94.2M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20263219367719-5752
Q1 20262611447985-6815

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$94.2M−$521K$8.9M$58.8M−$94.7M
Q1 2026−$125M−$820K$390M−$12.8M−$126M
Q4 2025−$92.9M−$458K—$9.8M−$93.4M
Q3 2025−$111M−$863K$3.1M−$57.2M−$112M
Q2 2025−$85.9M−$3.2M$7.1M$40.8M−$89.1M
Q1 2025−$88.5M−$1.2M$4.4M$170M−$89.7M
Q4 2024−$66.9M−$1.0M$551M$52.7M−$67.9M
Q3 2024−$62.8M−$528K$58.8M−$15.1M−$63.4M

Crinetics Pharmaceuticals: income statement and cash flow

Crinetics Pharmaceuticals, Q2 2026: revenue $25.1M (24× year over year), operating margin -527.3%. The chart follows the revenue to costs, profit and cash.

Crinetics Pharmaceuticals: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.